ERBB2 and breast carcinoma: The presence/absence of tumor-infiltrating NK cells (TI-NK cells) in treatment-naive breast tumor biopsies was associated to benefit/resistance to anti-HER2 antibody-based neoadjuvant treatment in HER2+ breast cancer patients with primary disease [7].